RUA Stock Overview
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
RUA Life Sciences plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.54 |
52 Week High | UK£0.67 |
52 Week Low | UK£0.31 |
Beta | 1.27 |
1 Month Change | 13.68% |
3 Month Change | 56.52% |
1 Year Change | 0.93% |
3 Year Change | -37.57% |
5 Year Change | 14.89% |
Change since IPO | -96.10% |
Recent News & Updates
Shareholder Returns
RUA | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -10.7% | 3.9% | 0.8% |
1Y | 0.9% | -2.9% | -4.6% |
Return vs Industry: RUA exceeded the UK Medical Equipment industry which returned -4.8% over the past year.
Return vs Market: RUA exceeded the UK Market which returned -3.7% over the past year.
Price Volatility
RUA volatility | |
---|---|
RUA Average Weekly Movement | 14.5% |
Medical Equipment Industry Average Movement | 8.3% |
Market Average Movement | 5.1% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: RUA is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: RUA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 38 | n/a | https://rualifesciences.com |
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves.
RUA Life Sciences plc Fundamentals Summary
RUA fundamental statistics | |
---|---|
Market Cap | UK£11.98m |
Earnings (TTM) | -UK£1.90m |
Revenue (TTM) | UK£2.02m |
5.9x
P/S Ratio-6.3x
P/E RatioIs RUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RUA income statement (TTM) | |
---|---|
Revenue | UK£2.02m |
Cost of Revenue | UK£316.00k |
Gross Profit | UK£1.71m |
Other Expenses | UK£3.60m |
Earnings | -UK£1.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.086 |
Gross Margin | 84.36% |
Net Profit Margin | -93.96% |
Debt/Equity Ratio | 8.2% |
How did RUA perform over the long term?
See historical performance and comparison